Research aims to find the cause of prevalence of osteoporosis in MS patients due to lack of research.
With a typical onset between the ages of 20 and 40, multiple sclerosis (MS) currently affects 2.8 million people worldwide and is the most common nontraumatic neurological disability in young adults. People with MS are often prescribed medications that could potentially affect bone health and lead to osteoporosis, a common problem among people with MS.
A recent study from the School of Clinical Sciences at Montash University in Australia, published in the Journal of Managed Care and Specialty Pharmacy by Michael Cahyadi ,aims to figure out the potential these medications have on areal bone mineral density (aBMD).
To find answers, researchers combed through data published in MEDLINE, Embase, Scopus, CINAHL and Web of Science and settled on 22 studies. They focused specifically on the effects of glucocorticoid, antidepressant, anticonvulsant, anxiolytic, opioid, and antipsychotic medication and found conflicting data, partly due to an insufficient number of studies.
Although research identified a significant inverse relationship between glucocorticoids and decreased femoral neck bone density, the authors report that the data is not comprehensive enough to confirm a direct correlation.
Antidepressant and anxiolytic use were not associated with loss of bone density but only five studies were found.
There was not enough data to conclude the effects of anticonvulsants, opioids and antipsychotics.
Although research is inconclusive the authors recommend that patients on these medications continue to be monitored for bone frailty as more evidence comes out.
“Future studies require attention to how medication use is measured, including reduced reliance on retrospective self-report data, which is known to suffer memory bias, and increased attention to measuring medication class, dose, mode, and duration of administration,” the authors write. “Additional high-quality studies with homogenous methodology exploring how medications influence aBMD and fracture risk in people with MS are required.”
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More